A spin-out from Duke University, Predigen is a global leader in the development of host gene expression signatures for use as prognostic, diagnostic, and therapeutic monitoring tools.
We are devoted to advancing the diagnostics field in areas of high unmet need, including, but not limited, to infectious disease, cardiovascular disease, autoimmune and inflammatory disease, drug response, and cancer.
Predigen was founded by six experienced leaders in the fields of biotechnology, precision medicine, infectious disease, and business management
GEOFFREY GINSBURG, MD, PhD
Dr. Geoffrey Ginsburg is the founding director for the Duke Center for Applied Genomics & Precision Medicine and of Duke MEDx. He also founded Genomic Medicine in the Duke Institute for Genome Sciences & Policy and the Center for Personalized Medicine, established in the Duke University Health System. He is Professor of Medicine, Pathology, and Biomedical Engineering. Dr. Ginsburg has pioneered translational genomics, and has led the development of predictive models for common, complex diseases using high dimensional genomic data. He is an internationally recognized expert in genomics and personalized medicine with over 200 published papers, and funding from NIH, DOD, DARPA, the Gates Foundation, and industry.
He has been a member of the Secretary of Veterans Affairs Advisory Council on Genomic Medicine, a member of the NIGMS External Scientific Panel for the Pharmacogenomics Research Network, the Board of External Experts for the NHLBI, the National Advisory Council for Human Genome Research at NIH, the Advisory Council for the National Center for Advancing Translational Sciences at NIH, and the World Economic Forum’s Global Agenda Council on The Future of the Health Sector. He is co-chair of the National Academies Roundtable on Genomics and Precision Health, founder of the Global Genomic Medicine Collaborative, and a member of the Advisory Committee to the Director of NIH.
CHRISTOPHER WOODS, MD, MPH
Dr. Christopher Woods is the Co-Director of the Hubert-Yeargan Center for Global Health. He is a professor in the Departments of Medicine and Pathology at Duke University; an adjunct professor in Epidemiology at the University of North Carolina at Chapel Hill School of Public Health; and an adjunct professor in the Emerging Infections Program at the Duke-National University of Singapore Graduate Medical School. Clinically, he serves as Chief of Infectious Diseases and clinical microbiology, and hospital epidemiologist for the Durham VA Health Care System. Dr. Woods is board-certified in internal medicine, infectious diseases, and medical microbiology. He currently serves as the Director of Graduate Studies and the MSc for Global Health in the Duke Global Health Institute.
Dr. Woods has published over 130 peer-reviewed articles and has a particular interest in development of medical microbiology capacity in the developing world and the epidemiology of emerging and re-emerging infectious diseases. His research focuses on the development of novel diagnostic approaches to infectious disease and the potential for interspecies transmission of pathogens. His genomic approach to harnessing the host response for diagnosis of infectious diseases has been called a paradigm shift in the field. Dr. Woods is a partner in the Southeastern Center for Emerging Biological Threats, core PI of the Southeastern Research Center for Excellence on Emerging Infections and Biodefense, and a leader in the NIH-funded Vaccine and Therapeutics Evaluation Unit at Duke.
EPHRAIM TSALIK, MD, PhD
Dr. Ephraim Tsalik is an Associate Professor of Medicine in the Center for Applied Genomics & Precision Medicine and the Division of Infectious Diseases at Duke University School of Medicine. Dr. Tsalik is also a faculty member in the Department of Molecular Genetics and Microbiology at Duke. In addition, he is a Staff Physician in the Emergency Department Service of the Durham VA Health Care System.
Dr. Tsalik’s research has focused on the development, evaluation, and promotion of diagnostics for acute infectious disease. He has made use of systems biology approaches to characterize the host response to infection, using these findings to drive the development of diagnostic and prognostic assays. Specific areas of interest include the differentiation of infectious from non-infectious disease; bacterial vs. viral infection; and using molecular data to redefine the sepsis syndrome. He is also the Associate Director of Diagnostics for the NIH-funded Antibacterial Resistance Leadership Group, where he interfaces with industry and academic partners to advance diagnostics development. Dr. Tsalik has engaged with regulatory authorities such as the FDA regarding host response biomarkers, speaking at their public workshop on Non-Microbial Biomarkers of Infection for In Vitro Diagnostic Device Use. He served on the NHLBI Working Group on Pneumonia, offering guidance on the host response to pneumonia.
GEOFFREY LING, MD
Dr. Geoffrey Ling is a clinician-scientist advancing technology as it pertains to improving the human condition. He serves as a Professor of Neurology and Neuroscience at the Uniformed Services University of the Health Sciences. Geoffrey is also an attending neurocritical care physician at Johns Hopkins Hospital and is board certified in both neurology and neurocritical care. Additionally, he is CEO of SunQ, LLC, which is a firm specializing in technology development for healthcare. He previously served as the Founding Director of the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA) and the Assistant Director for Medical Innovation of the Science Division at the White House Office of Science and Technology Policy. Geoffrey has published over 180 peer-reviewed articles, review articles and book chapters and one patent. He is a retired US Army colonel having retired after 21 years of active duty.
Brian Best has twenty-five years of operational experience in pharmaceutical, device and diagnostic companies. His diverse experience across all aspects of commercialization have led to his employment by and consulting to a variety of organizations, including COR Therapeutics, Millennium Pharmaceuticals, Premier, Duke Clinical Research Institute, Tethys, Geisinger Health System, Janssen Pharmaceuticals, Medscape, American College of Cardiology, CARRA, PCORI, and others.
In collaboration with DCRI, Mr. Best played a leading role in developing and managing the national CRUSADE registry, which altered the landscape of cardiovascular care in the US. Serving as CBO to CARRA, he helped secure > $40MM in capital to support a decade of research in pediatric rheumatology. As co-founder and former CEO of Ariste Medical, he helped fund and develop a drug-device combination product that is currently under FDA review.
DONNA CRENSHAW, PhD, MHA
Dr. Donna Crenshaw serves as executive director of MEDx, an innovative collaborative venture of the Duke University School of Medicine and the Pratt School of Engineering. Dr. Crenshaw, a life sciences professional with deep experience in bringing new health care technologies to market, manages MEDx strategy, oversees and leads MEDx operations, provides oversight for MEDx’s pilot research programs and colloquia, and develops external partnerships for the initiative.
Dr. Crenshaw previously served as director of strategic partnerships for the Duke Center for Applied Genomics & Precision Medicine, and as senior research scientist for the Joseph and Kathleen Bryan Alzheimer’s Disease Research Institute at Duke. Dr. Crenshaw possesses a wealth of experience as both a university research scientist and as an industry expert in technology evaluation, licensing, intellectual property, and marketing.